Talisman
Phase 2 Study Evaluating Different Medications to See If They May Help with GPRC5D-related Oral Events
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 210 patients (estimated)
- Sponsors
- Johnson & Johnson
- Tags
- Bispecific Antibody, CD3, GPRC5D, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1950
- NCT Identifier
- NCT06500884
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.